![Patrik Renblad](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 26 957 $ al 31/08/2026
Patrik Renblad is currently the Chief Financial Officer at Cantargia AB since 2023.
Prior to this, he was the Chief Financial Officer at SynAct Pharma AB from 2022 to 2023.
He also worked as a Finance Director-R&D at LEO Pharma A. Mr. Renblad is a graduate of the University of Lund.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CANTARGIA AB 0,05 % | 31/12/2024 | 141.405 ( 0,05 % ) | 26 957 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CANTARGIA AB | Director Financiero/CFO | 15/06/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| SYNACT PHARMA AB | Director Financiero/CFO | 15/05/2023 |
LEO Pharma A/S
 LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Health Services |
University of Lund
 University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
 Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
SynAct Pharma AB
 SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
